Search Results

There are 1930 results for: content related to: Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease

  1. Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

    High-Density Lipoproteins: Structure, Metabolism, Function, and Therapeutics

    Anatol Kontush, M. John Chapman, Pages: 423–523, 2011

    Published Online : 28 NOV 2011, DOI: 10.1002/9781118158678.ch11

  2. Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

    Clinical Pharmacology & Therapeutics

    Volume 91, Issue 1, January 2012, Pages: 109–122, D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena and J A Wagner

    Article first published online : 30 NOV 2011, DOI: 10.1038/clpt.2011.271

  3. You have free access to this content
    Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities

    British Journal of Pharmacology

    Volume 167, Issue 6, November 2012, Pages: 1177–1194, K Mahdy Ali, A Wonnerth, K Huber and J Wojta

    Article first published online : 19 OCT 2012, DOI: 10.1111/j.1476-5381.2012.02081.x

  4. You have free access to this content
    Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 74, Issue 1, July 2012, Pages: 116–124, Rajesh Krishna, Daria Stypinski, Melissa Ali, Amit Garg, Josee Cote, Andrea Maes, Bruce DeGroot, Yang Liu, Susie Li, Sandra M. Connolly, John A. Wagner and S. Aubrey Stoch

    Article first published online : 11 JUN 2012, DOI: 10.1111/j.1365-2125.2012.04171.x

  5. Atherosclerosis II: HDL Elevation

    Standard Article

    Burger's Medicinal Chemistry and Drug Discovery

    Amjad Ali, Julianne A. Hunt and Peter J. Sinclair

    Published Online : 15 SEP 2010, DOI: 10.1002/0471266949.bmc193

  6. Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 49, Issue 1, January 2009, Pages: 80–87, Dr Rajesh Krishna, Dr Arthur J. Bergman, Dr Bo Jin, Dr Amit Garg, Dr Brad Roadcap, Ms Rita Chiou, Mr James Dru, Ms Josee Cote, Dr Tine Laethem, Dr Regina W. Wang, Dr Varsha Didolkar, Dr Eva Vets, Dr Keith Gottesdiener and Dr John A. Wagner

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008326718

  7. Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches

    The Journal of Clinical Pharmacology

    David S. Small, Alice Ban Ke, Stephen D. Hall, Nathan Mantlo, Matthew Rotelli and Stuart Friedrich

    Article first published online : 20 FEB 2015, DOI: 10.1002/jcph.472

  8. You have free access to this content
    Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion

    Cardiovascular Therapeutics

    Volume 29, Issue 6, December 2011, Pages: e89–e99, Paul J. W. H. Kappelle, Arie van Tol, Bruce H. R. Wolffenbuttel and Robin P. F. Dullaart

    Article first published online : 14 JUL 2010, DOI: 10.1111/j.1755-5922.2010.00201.x

  9. Biologic Activities

    High-Density Lipoproteins: Structure, Metabolism, Function, and Therapeutics

    Anatol Kontush, M. John Chapman, Pages: 192–303, 2011

    Published Online : 28 NOV 2011, DOI: 10.1002/9781118158678.ch7

  10. You have free access to this content
    Anacetrapib: Hope for CETP Inhibitors?

    Cardiovascular Therapeutics

    Volume 29, Issue 5, October 2011, Pages: 327–339, Ronen Gurfinkel and Tisha R. Joy

    Article first published online : 9 APR 2010, DOI: 10.1111/j.1755-5922.2010.00142.x

  11. Effects of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib

    The Journal of Clinical Pharmacology

    Volume 53, Issue 7, July 2013, Pages: 746–752, Matt S. Anderson, Josee Cote, Yang Liu, Daria Stypinski, Patrice Auger, Anne Hohnstein, Scott Rasmussen, Amy O. Johnson-Levonas and David E. Gutstein

    Article first published online : 14 MAY 2013, DOI: 10.1002/jcph.97

  12. High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm

    Clinical Pharmacology & Therapeutics

    Volume 96, Issue 1, July 2014, Pages: 48–56, S Tuteja and D J Rader

    Article first published online : 8 APR 2014, DOI: 10.1038/clpt.2014.79

  13. Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 6, December 2008, Pages: 679–683, R Krishna, AJ Bergman, B Jin, M Fallon, J Cote, P Van Hoydonck, T Laethem, IN Gendrano III, K Van Dyck, D Hilliard, O Laterza, K Snyder, C Chavez-Eng, R Lutz, J Chen, DM Bloomfield, M De Smet, LM Van Bortel, M Gutierrez, N Al-Huniti, K Dykstra, KM Gottesdiener and JA Wagner

    Article first published online : 25 JUN 2008, DOI: 10.1038/clpt.2008.109

  14. Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 3, March 2011, Pages: 436–439, Dr Amit Garg, Dr Andrea Maes, Ms Christy Corr, Dr Bo Jin, Mr Tarun Wadhwa, Mr Nikhil Handa, Dr Kristien Van Dyck, Dr Inge De Lepeleire, Dr Jinesh Shah, Dr John A. Wagner and Dr Rajesh Krishna

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010368676

  15. You have free access to this content
    Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 68, Issue 4, October 2009, Pages: 535–545, Rajesh Krishna, Amit Garg, Deborah Panebianco, Josee Cote, Arthur J. Bergman, Pascale Van Hoydonck, Tine Laethem, Kristien Van Dyck, Jingjing Chen, Cynthia Chavez-Eng, Laura Archer, Ryan Lutz, Deborah Hilliard, Karen Snyder, Bo Jin, Luc Van Bortel, Kenneth C. Lasseter, Nidal Al-Huniti, Kevin Dykstra, Keith Gottesdiener and John A. Wagner

    Article first published online : 18 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03465.x

  16. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib

    The Journal of Clinical Pharmacology

    Volume 54, Issue 11, November 2014, Pages: 1247–1255, Brett Lauring, Xiujiang (Susie) Li, Yang Liu, Christy Corr, Nicole Lazarus, Josee Cote, Patrick Larson, Amy O. Johnson Levonas, Kenneth C. Lasseter, Richard A. Preston, William B. Smith, Eseng Lai and John A. Wagner

    Article first published online : 6 JUN 2014, DOI: 10.1002/jcph.320

  17. Synthesis of stable isotope labeled anacetrapib, its major metabolites and [14C]anacetrapib

    Journal of Labelled Compounds and Radiopharmaceuticals

    Volume 56, Issue 12, October 2013, Pages: 600–608, Jeffrey T. Kuethe, Eric D. Soli, Pernilla Royster and Catherine A. Quinn

    Article first published online : 9 JUL 2013, DOI: 10.1002/jlcr.3073

  18. You have free access to this content
    Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 67, Issue 5, May 2009, Pages: 520–526, Rajesh Krishna, Amit Garg, Bo Jin, Sara Sadeghi Keshavarz, Frederick A. Bieberdorf, Jeffrey Chodakewitz and John A. Wagner

    Article first published online : 4 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03385.x

  19. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects

    Biopharmaceutics & Drug Disposition

    Volume 32, Issue 9, December 2011, Pages: 525–529, Rajesh Krishna, Daria Stypinski, Melissa Ali, Amit Garg, Isaias Noel Gendrano III, Andrea Maes, Bruce DeGroot, Yang Liu, Susie Li, Sandra M. Connolly, John A. Wagner and S. Aubrey Stoch

    Article first published online : 24 NOV 2011, DOI: 10.1002/bdd.776

  20. High-Density Lipoprotein: A Novel Target for Antirestenosis Therapy

    Clinical and Translational Science

    Volume 7, Issue 6, December 2014, Pages: 500–511, Kai Yin and Devendra K. Agrawal

    Article first published online : 15 JUL 2014, DOI: 10.1111/cts.12186